Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $540,485.27 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction on Monday, July 7th. The stock was sold at an average price of $46.67, for a total transaction of $540,485.27. Following the sale, the chief financial officer directly owned 58,078 shares of the company's stock, valued at $2,710,500.26. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, June 23rd, Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75.
• On Wednesday, May 28th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $52.98, for a total transaction of $613,561.38.
• On Thursday, May 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.22, for a total value of $697,407.82.
• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.50, for a total value of $330,058.50.

Hims & Hers Health Stock Up 1.1%

Shares of NYSE:HIMS traded up $0.54 during trading on Tuesday, hitting $48.96. The stock had a trading volume of 30,532,151 shares, compared to its average volume of 23,512,684. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The company has a market capitalization of $10.96 billion, a PE ratio of 70.96, a PEG ratio of 1.76 and a beta of 2.02. The firm's fifty day moving average is $52.62 and its 200 day moving average is $40.54.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on HIMS. TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Piper Sandler restated a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Morgan Stanley restated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $39.58.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC grew its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.